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ABSTRACT
Gliomas are the most common primary and aggressive intracranial tumors, represent 80% of malignant brain tumors, and despite the fact that are 
relatively rare tumors are responsible for significant mortality and morbidity. Glioblastoma multiforme (GBM) or diffuse astrocytoma, WHO grade 
IV, is the most common and aggressive primary central nervous system malignancy, represents 45% of all gliomas, shows an average incidence of 
3.19/100,000 individuals, its median age of diagnosis is 64 years, and the median survival is 15 months as the 5-year relative survival is 5%. Previous 
studies have investigated the possible role of genetic and environmental factors in GBM pathogenesis; however, the majority of GBM cases were 
sporadic and certain risk factors have not been detected. GBM is divided into primary and secondary subtypes which develop through different 
genetic pathways, affect patients at different ages, and have differences in clinical outcomes, as show a great morphological and genetic heterogeneity. 
The role of traumatic brain injury (TBI) in GBM formation has been investigated in many previous reports which have hypothesized that TBI may 
predispose to gliomagenesis; however, the outcomes were highly controversial. Some of those researches have proposed a supposed pathogenesis 
model that involves a post-traumatic inflammation, stem and progenitor cell transformation, and gliomagenesis. Other similar studies have involved 
transcription factors associated with TBI such as p53, hypoxia-inducible factor-1a (HIF-1a), and c-Myc. On the other hand, the possibility of a pre-
existing tumor rather than a trauma-induced tumor is very possible in such cases.
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INTRODUCTION
Gliomas are primary brain tumors, and classified according to their 
supposed origin cell, as astrocytic tumors (astrocytoma, anaplastic 
astrocytoma, and glioblastoma), oligodendrogliomas, ependymomas, 
and mixed gliomas [1]. They are the most common primary and 
aggressive central nervous system tumors which account for almost 
80% of all malignant primary brain tumors [1,2]. In general, gliomas 
are more common in males than females, with the exception of 
pilocytic astrocytoma, which occurs at similar rates in males and 
females [3]. Anaplastic astrocytoma and glioblastoma multiforme 
(GBM) increase in incidence with age, peaking in the 75–84 age group. 
Oligodendrogliomas and oligoastrocytomas are the most common in 
the 35–44 age group [4].
GBM or diffuse astrocytoma, WHO grade IV [5], is the most malignant 
and frequent type of primary astrocytomas, as accounts for more than 
60% of all brain tumors in adults [6], is characterized by extremely poor 
prognosis, despite developments in molecular Biology and genetics and 
new anti-neoplasmatic treatments and shows a great morphological 
and genetic heterogeneity, whereas its median survival is about 14–15 
months after its diagnosis [7,8].
GBM’s global incidence is <10/100,000 individuals [8], accounts for 
50% of all gliomas age but the peak incidence concerns individuals 
between ages 55 and 60 [9], is the 3rd principal cause of death from 
cancer in individuals 15 and 34 years of age [10], whereas the GBM 
incidence ratio is higher in males than in females [8,9].
Brain neoplasms etiology has not yet been clarified as no underlying 
carcinogenetic factors have been identified. Until now the only 
confirmed risk factor is exposure to high dose ionizing radiation [11,12]; 
however, the overall risk of developing GBM following radiotherapy is 
2.5% [13].
Extensive retrospective cohort data showed a higher risk of glioma 
in pediatric populations after exposure to therapeutic intracranial 
radiation. Data in adults are more limited but showed increased risk in 
certain groups exposed to radiation. No evidence was found between 
risk of developing GBM and routine exposure to diagnostic radiation in 
both children and adults [14].
Furthermore, patients who received treatment for acute lymphoid 
leukemia (ALL) were more prone to develop GBM, as a result of 
complications arising from the leukemia or the chemotherapeutic 
agents used to treat ALL [13]. No conclusive association has been found 
between GBM and environmental factors such as smoking, dietary risk 
factors, cell phones or electromagnetic field, human cytomegalovirus 
infection, occupational risk factors, and pesticide exposure [1,12,15-17]. 
Few studies have shown the possible role of ovarian steroid hormones in 
development of GBM [18]. It has also been proposed that infections and 
allergic diseases may have a protective effect for GBM that may be due 
to the activation of immune surveillance mechanism [5,11]. Gliomas also 
tend to run in families but the susceptibility gene is still unidentified [11].
Genetic predisposition has been observed only in 5–10% of cases [15]. 
Family history has been shown to be associated with an increased risk 
of GBM. Recent genome-wide association studies have indicated single 
nucleotide polymorphisms (SNPs) that can increase the predisposition 
to glioma development [19-24]. Such a significant SNP is located on 
chromosome 8q24.21, within the locus of a long non-coding RNA named 
CCDC26, which increases glioma risk approximately 5 times [19-21]. 
Infrequent genetic diseases such as neurofibromatosis type 1 and 
type 2, and tuberous sclerosis, were found to be associated with 
increased GBM incidence [11,12,16]. Environmental risk factors in GBM 
development remain poorly defined, as already has been mentioned, 
with the exception of exposure to ionizing radiation. Another possible 
risk factor for gliomagenesis is traumatic brain injury (TBI) [25-27].
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The present review aims to present an overview of the current 
knowledge regarding the pathogenesis of GBM mainly focusing on the 
possible role of previous traumatic brain injuries and its association 
with GBM development, according to the international literature’’.
EPIDEMIOLOGICAL RESEARCH
Several epidemiological studies have attempted to investigate the 
possible association between previous TBI and GBM development; 
however, the findings were controversial.
TBI-induced gliomas incidence cannot be determined as post traumatic 
gliomas have not been included in brain tumors statistical reports, except 
from epidemiological studies. Munch et al. [28] carried out a nationwide 
cohort study and found that the incidence of post-traumatic glioma among 
individuals with a brain trauma was 3/10,000. However, the estimated 
incidence was based on a special individual group and not to the entire 
population. Moreover, post-traumatic glioma incidence is difficult to be 
assessed due to the frequently significant time period between TBI and 
glioma development. The authors investigated over 400,000 individuals 
and recorded no association between TBI and risk of malignant glioma 
during the first 4 years after TBI. On the contrary, the same research 
showed that TBI was associated with long-term protection from 
malignant gliomas. Inskip et al. [29] assessed the incidence of brain and 
other intracranial tumors following head trauma in a cohort of 228,055 
Danish hospitalized individuals and recorded a slightly increased overall 
incidence of intracranial tumors, but no association between head trauma 
and malignant astrocytic tumors, such as malignant astrocytoma and 
GBM. A limitation of this study was the short follow-up time. Another 
population-based cohort study which was based on over 300,000 
individuals who had documented TBI observed 400 cases of brain tumors, 
but no overall association between TBIs and intracranial tumors was 
recorded [30]. A proportion of those cases were excluded because they 
occurred within the 1st year after the TBI. However, the outcomes did not 
refer the specific risks for malignant astrocytic tumors.
A similar, population-based study in Taiwan aimed to assess the risk 
of having a diagnosis of malignant brain tumors within 3 years after a 
TBI [31]. The investigators observed an increased risk for not otherwise 
specified malignant brain tumors and suggested a positive association 
between TBI and the relatively short-term development of brain 
malignant neoplasms, after adjusting for sociodemographic parameters. 
The authors found that the risk of developing an intracranial malignancy 
within 3 years of TBI was 4.67 times greater for individuals with TBI 
compared to those without injury. The same report also showed a 
statistically significant association between TBI severity and brain 
tumor development [31]. Monteiro et al. [32] observed that individuals 
with TBI showed an increased risk of developing brain tumors and they 
also found that after adjusting for age, gender, and schooling, two or 
more brain injuries could lead to an association between brain injury 
severity and frequency and subsequent tumor development.
A multicenter case-control study in a group [33] of 801 children 
showed that the odds ratio of developing a primary brain tumor after 
previous TBI was 1.4 and was remained after adjusting for age, gender, 
and location. Another finding was that multiple brain injuries may be 
much more likely to cause a primary tumor than a single injury and was 
also recorded that the severity of the injury is possible to be associated 
with the risk of developing a brain tumor.
Controversial outcomes recorded after performing few case-control 
studies which investigated the risk for malignant astrocytoma/
glioma after a head trauma and showed positive [34,35] and invalid 
associations [36,37].
Previous case reports proposed the possible pathogenesis of GBMs which 
occurred up to 20 years later at the location of TBIs as a result of neoplastic 
transformation of damaged astrocytes [25-27,38-42]. Similarly, other 
case report studies suggested that acquired head injuries, which may 
occur as a result of a brain contusion, may predispose to the appearance 
of malignant gliomas [26,37,39,43-50], whereas a definite evidence for 
a possible causative role of TBI in gliomas and GBMs pathogenesis has 
been suggested by a small number of case report studies [41, 46].
The possible association between TBI and gliomagenesis has not been 
resolved yet [51], as only a few documented cases have been demonstrated 
that association. Moreover, it was necessary to be established some 
objectively criteria for a glioma to be considered as a post-traumatic. 
Zhou [27], based on previous investigators, reported the following criteria 
for post-traumatic glioma determination: (1) Good health condition of 
the individual before being injured, (2) damage must be serious enough 
to cause brain injury and to trigger a secondary repair procedure, (3) 
tumor and injury must be concerned the same location, (4) it should be 
confirmed the histopathological environment of tumor and brain injury, 
(5) the time difference between brain injury and the appearance of the 
tumor should be more than a year, as a longer latent period is considered 
to be a stronger evidence of a causal relation, (6) the trauma should occur 
from an external force, (7) clinical signs such as bleeding, scars, and 
secondary edema must be induced by the tumor and not the injury, and 
(8) tumor tissue should be a direct continuation of the traumatic scar, and 
not be adjacent in it or separated by a healthy section. Anselmi et al. [25] 
reported two cases who developed brain gliomas in the scar of a previous 
TBI and met the mentioned criteria for a causal relationship between TBI 
and glioma development. Moreover, other investigators have suggested 
more pathologic criteria for the diagnosis of a post-traumatic glioma, such 
as a computed tomography (CT) or magnetic resonance imaging (MRI) 
immediately after the TBI that displays evidence of brain injury but no 
tumor and histopathological confirmation [52].
DISCUSSION
Possible pathogenetic mechanisms
Recruitment of neural stem cells (NSCs) to injury location
Adult NSCs are located to the sub-ventricular zone of the lateral 
ventricles and the sub-granular zone of the hippocampal dentate 
gyrus [53], whereas NSCs or progenitor cells may also located at 
cortical areas [54]. NSCs in neurogenic regions are responsible for the 
generation of neurons, astrocytes, and oligodendrocytes. In case of a TBI, 
those NSCs and descendant progenitor cells migrate chemotactically to 
the brain injury locations and contribute to the repair and recovery 
procedures [55-59]. That described chemoattraction-mediated 
migration has been detected in several injuries which is characterized 
by ischemia and demyelination [55].
A case report study showed that the examined cases developed 
GBM at their brain injury location several years later and suggested 
an hypothesis that in some individuals, an underlying biological 
susceptibility predisposes them to gliomagenesis after brain trauma. 
With regard to the possible pathogenic mechanisms they proposed that 
the inflammatory reaction which is activated after TBI is related to the 
oncogenic transformation of NSCs and progenitor cells that migrate 
chemotactically to the injured region in response to inflammation [60].
It has been proven that chronic inflammation is a crucial predisposing 
factor for many solid tumors in various organs [61]. However, such an 
association has not been investigated in gliomagenesis because of the 
special brain immune properties. The authors suggested that in a subset of 
patients, brain post-traumatic inflammation may predispose neural cells 
toward oncogenic transformation and glioma appearance. Therefore, it is 
possible that GBM may arise from NSCs or progenitor cells transformation 
as those cells migrate to the injury location to repair tissue damage [60].
It has been reported that several neural cell types that migrate to TBI 
sites are capable of undergoing oncogenic transformation, such as 
astrocytes from injured brain tissue which demonstrate long-term 
activity, suggesting the possibility of a return to multipotent stem 
cell under certain conditions [62,63]. Based on the observation that 
neurogenic regions in the brain are sensitive to chemical oncogenesis, 
it has been suggested the NSCs oncogenic potential [54,64,65].
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Moreover, experimental studies have indicated that even terminally 
differentiated brain cells, such as neurons and astrocytes, can contribute 
to GBM development by undergoing dedifferentiation induced by 
genetic alterations [66,67], whereas ependymal cells, which cover the 
inner walls of the ventricles, may also proliferate and differentiate into 
neuroblasts and astrocytes after TBI in mice and humans [68,69].
Experimental models implicate overexpression of oncogenes and 
inactivation of tumor suppressor genes in NSCs suggesting that they can 
lead to GBM development [53]. That assumption has been supported by 
the observation that GBMs have been frequently observed in the peri-
ventricular zone or in direct contact with the subventricular zone [70-72].
Role of astrocytes
Previous reviews, based on histopathological findings, showed that 
after a structural brain injury, reactive astrocytes are responsible 
for a localized inflammatory reaction which leads to astrogliosis and 
glial scar formation [73-75]. After brain parenchyma damage, occurs 
reactive astrocytes proliferation, alteration of their morphology, and 
migration to the injury location, where are able to promote or inhibit 
the generation of neurons from NSCs and progenitor cells [62,76].
Adult periventricular NSCs give rise to glia cells, astrocytes and 
oligodendrocytes, are also activated in astrogliosis as an element of the 
repair mechanism in structural brain injury [74].
Periventricular NSCs and reactive astrocytes express glial fibrillary 
acidic protein [77] which is also expressed in most astrocytic tumors, 
GBM included in the study. It has been suggested that GBMs can be 
developed from astrocytic origin cells and oligodendrocyte progenitor 
cells, dependent on the subtypes [77,78].
Munch et al. [28], in a nationwide cohort study reported that any 
condition which leads to astrogliosis and includes any type of structural 
brain injury which causes brain parenchyma damage, may be associated 
with long-term risk especially for malignant astrocytic tumors. The 
authors investigated the potential association between structural brain 
injury caused by trauma, which causes reactive astrogliosis and long-
term risk for malignant tumor of astrocytic origin (WHO grades III 
and IV), and observed no association between structural brain injury 
and malignant astrocytic tumors within the first 5 years of follow-up. 
On the contrary, it was reported a protective effect of astrogliosis-
causing injuries 5 or more years after the structural brain injury [28].
Inflammatory reaction at brain injury location
It has been documented that at the brain injury location an inflammatory 
reaction occurs [79-82]. During the acute post-trauma period, a sequential 
mobilization of resident brain microglia and myeloid inflammatory cells to 
the injury location has been detected. Peripheral inflammatory cells such 
as neutrophils, monocytes, and eosinophils migrate and are recruited to 
the injury location within hours and can remain for extended time periods 
[79]. Those inflammatory cells can contribute to oncogenesis due to 
production of reactive oxygen species (ROS) and reactive nitrogen species, 
which have mutagenic properties, or due to growth factors expression 
of cytokines and chemokines that have mitogenic effects on NSCs and 
progenitors cells, in addition to elongating the inflammatory reaction 
[80,81]. At TBI location, inflammatory cytokines such as interleukin (IL)-1, 
IL-6, IL-8, IL-10, tumor necrosis factor-α, and monocyte chemoattractant 
protein-1 (MCP-1) are up-regulated and contribute to the myeloid 
immune cells recruitment [81]. IL-4 and IL-13 are able to activate the IL-
4Ra receptor on immune system cells, which leads to similar downstream 
responses, and results in the release of chemoattractants such as eotaxin 
and MCP-1. Those chemotactic proteins lead to the migration and 
recruitment of eosinophils and monocytes into the injury location [81,83]. 
Moreover, it has been proven that SNPs in IL-13 and IL-4Ra may contribute 
to an increased risk of GBM development [84].
Regarding the role of eosinophils, they are implicated in the 
initiation and progression of GBM [85]. Activated eosinophils 
produce eosinophil-derived neurotoxin (EDN, RNase 2), eosinophil 
cationic protein (RNase 3), and eosinophil protein X that have been 
experimentally shown to cause cellular damage in neural tissues during 
their degranulation [85,86]. EDN has also been identified as a toll-like 
receptor-2 (TLR2) ligand that can promote in vivo activation of murine 
dendritic cells (DCs) [87]. In experimental GBM models, TLR2-ligands 
have been found to induce an influx of tumor-infiltrating immune cells 
(DCs, CD8+ T effector cells) and significant tumor regression [88,89], 
which raises the possibility that EDN may operate comparatively.
Moreover, eosinophil peroxidases generate ROS, which may lead to 
mutagenesis [61,85,90].
Inflammation is responsible for healing wounds, maintaining tissue 
homeostasis and is involved in tumor pathogenesis, as induce DNA 
damage and genetic instability. Especially, chronic inflammation may 
cause malignant transformation through mutations or epigenetic 
pathways, as can activate various oncogenes, such as c-Myc which 
is involved in inflammatory reactions and is often deregulated, and 
malignant transformation. It is also associated with increased cellular 
proliferation, whereas can lead to induction of p53-dependent 
apoptosis following DNA damage [91]. c-Myc expression may be a 
marker of brain trauma as has been detected by immunohistochemical 
examination of rat brains [92]. p53 protein induces neuronal apoptosis 
and is responsible for regeneration after TBI, due to the activation of 
the p53-induced death domain protein [93].
The association between trauma and inflammation is more promptly 
recognized in non-brain tumors such as pancreas and liver. After an 
acute injury an acute inflammation occurs [80,82] and implicates an 
oxidative cascade and inflammatory cells production. However, this 
phase is temporary, as in some cases exists a balance between the 
immune/inflammatory and regenerative responses, which if it modifies 
will increase the probability of malignant transformation [82].
Injury and inflammation have been associated with various types of 
cancer or other recurrent trauma. However, its implication in GBM 
development has not been confirmed by epidemiological studies [94].
Xiong et al. [95] used animal models for investigating TBI and recorded 
oxidative stress and calcium homeostasis disruption, but no brain cancer.
Arif et al. [96] examined GBM and its associations with c-Myc, hypoxia-
inducible factor-1a (HIF-1a), and p53, FOXO3, STAT3, and AP2, and 
other transcription factors that regulate the transformed phenotype. 
It was reported that GBM obtains metabolic reprogramming, and that 
the voltage-dependent anion channel 1 (VDAC1), a mitochondrial 
protein that controls cell energy and metabolic homeostasis, could be 
silenced to invert the reprogrammed metabolism. VDAC1 reduction 
could modify transcription factor profiles, as the expression levels 
of transcription factors such as p53, HIF-1a, and c-Myc were mostly 
affected, as led to an increase in p53 expression and a decrease in HIF-1a 
and c-Myc expression, whereas could lead to normalization of malignant 
functions such as cell proliferation, loss of differentiation, and aerobic 
glycolysis. Those transcription factors are involved in the regulation of 
cell metabolism, growth, proliferation, and differentiation, therefore 
regulate the expression of several molecules and signaling pathways 
which maintain the glycolytic metabolism. It is possible that regulation 
of VDAC1 and the mentioned transcription factors may be involved in 
TBI and metabolic reprogramming and should be investigated as factors 
of a possible association between TBI and GBM pathogenesis [92,93,97].
HIF-1a is a transcriptional regulator of cellular and developmental response 
to hypoxia and has been proposed that involved in the regenerative 
treatment of TBI [97], whereas has also been used to treat brain edema 
and disruption of the blood-brain barrier in patients with TBI [98].
After occurrence of TBI the Warburg effect and HIF-1a activation in 
inflammatory reactions may be related to each other [99-101]. HIF-1a 
and the c-Myc oncogene play a role in inflammation. Therefore, it has 
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been hypothesized that these transcription factors and inflammation 
have a function in the development of GBMs after TBI. Trauma-associated 
gliomagenesis may be explained by TBI-induced inflammation, which 
leads to malignant transformation of adjacent neural progenitor cells, 
as already has mentioned [60].
Animal models have been used for TBI 
investigations [82,92,93,95-98,100,101]; however, no brain cancers were 
initiated by skull trauma in these laboratory animals. An explanation 
could be the long period which is needed for such a follow-up.
A possible mechanism suggested that TBI may alter the energy 
metabolism of the brain by disorganizing the transduction pathways 
and calcium transport into mitochondrial. Consequently, it is possible 
that the induction of oxidative stress and the disorganization of cellular 
calcium homeostasis play crucial roles in TBI [95].
CONCLUSION
Epidemiological studies have not shown a definitive association between 
TBI and increased risk of developing GBM, finding that could reflect the 
fact that the association, if it exists, is not a direct one, which means that 
there must be additional factors, as co-factors, involved in the etiology 
of glioma. Moreover, large study populations are mandatory because of 
the relatively low prevalence of brain tumors and the low incidence of 
head injuries experimental studies have proposed that trauma can act 
as a co-carcinogen factor in cancer initiation, finding that corresponds 
to Knudson’s theory of “Two Hits.” It is possible that an underlying 
susceptibility in a subset of individuals with TBI may predispose them 
to gliomagenesis. Three models that must be investigated include 
neuroinflammation and mutagenesis in NSCs and progenitor cells 
which are recruited to the injury location, the influence of chronic 
inflammation, and the influence of astrocytic proliferation after TBI. 
It is required that the examined association should be confirmed by 
additional experimental researches using modern medical technologies 
such as CT/MRI after a brain trauma.
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